MyPal ADULT study protocol:A randomised clinical trial of the MyPal ePRO-based early palliative care system in adult patients with haematological malignancies

Scarfò, L. and Karamanidou, C. and Doubek, M. and Garani-Papadatos, T. and Didi, J. and Pontikoglou, C. and Ling, J. and Payne, C. and Papadaki, H.A. and Rosenquist, R. and Stavroyianni, N. and Payne, S. and Ghia, P. and Natsiavas, P. and Maramis, C. and Stamatopoulos, K. (2021) MyPal ADULT study protocol:A randomised clinical trial of the MyPal ePRO-based early palliative care system in adult patients with haematological malignancies. BMJ Open, 11 (11). ISSN 2044-6055

Full text not available from this repository.

Abstract

Introduction The systematic collection of electronic patient-reported outcome (ePRO) in the routine care of patients with chronic haematological malignancies such as chronic lymphocytic leukaemia (CLL) and myelodysplasia syndromes (MDS) can constitute a very ambitious but worthwhile challenge. MyPal is a Horizon 2020 Research & Innovation Action aiming to meet this challenge and foster palliative care for patients with CLL or MDS by leveraging ePRO systems to adapt to the personal needs of patients and caregiver(s). Methods and analysis In this interventional randomised trial, 300 patients with CLL or MDS will be recruited across Europe. Patients will be randomly allocated to early palliative care using the MyPal system (n=150) versus standard care including general palliative care if needed (n=150). Patients in the experimental arm will be given access to the MyPal digital health platform which consists of purposely designed software available on smartphones and/or tablets. The platform entails different functionalities including physical and psychoemotional symptom reporting via regular questionnaire completion, spontaneous self-reporting, motivational messages, medication management and a personalised search engine for health information. Data on patients' activity (daily steps and sleep quality) will be automatically collected via wearable devices. Ethics and dissemination The integration of ePROs via mobile applications has raised ethical concerns regarding inclusion criteria, information provided to participants, free and voluntary consent, and respect for their autonomy. These have been carefully addressed by a multidisciplinary team. Data processing, dissemination and exploitation of the study findings will take place in full compliance with European Union data protection law. A participatory design was adopted in the development of the digital platform involving focus groups and discussions with patients to identify needs and preferences. The protocol was approved by the ethics committees of San Raffaele (8/2020), Thessaloniki 'George Papanikolaou' Hospital (849), Karolinska Institutet (20.10.2020), University General Hospital of Heraklion (07/15.4.2020) and University of Brno (01-120220/EK). Trial registration number NCT04370457. ©

Item Type:
Journal Article
Journal or Publication Title:
BMJ Open
Uncontrolled Keywords:
/dk/atira/pure/subjectarea/asjc/2700
Subjects:
ID Code:
162660
Deposited By:
Deposited On:
25 Nov 2021 16:10
Refereed?:
Yes
Published?:
Published
Last Modified:
30 Nov 2021 16:46